Publicaciones en las que colabora con Rubén Hernández Alcoceba (22)

2022

  1. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

2021

  1. Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

    Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221

  2. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

2019

  1. Danio rerio as model organism for adenoviral vector evaluation

    Genes, Vol. 10, Núm. 12

  2. Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice

    Hepatology, Vol. 70, Núm. 1, pp. 108-126

2018

  1. Brain copper storage after genetic long-term correction in a mouse model of Wilson disease

    Neurology: Genetics, Vol. 4, Núm. 3

  2. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry

    Journal of Hepatology

2017

  1. Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis

    Human Gene Therapy Clinical Development, Vol. 28, Núm. 2, pp. 68-73

2016

  1. A versatile vector for in vivo monitoring of type I interferon induction and signaling

    PLoS ONE, Vol. 11, Núm. 3

  2. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 419-426

2015

  1. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

  2. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver

    Liver International, Vol. 35, Núm. 4, pp. 1274-1289

2013

  1. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

2012

  1. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

2011

  1. Gene therapy of liver cancer: An update

    Journal Africain du Cancer, Vol. 3, Núm. 3, pp. 180-192

  2. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

    Gut, Vol. 60, Núm. 3, pp. 341-349

  3. Self-inactivating helper virus for the production of high-capacity adenoviral vectors

    Gene Therapy, Vol. 18, Núm. 11, pp. 1025-1033

2010

  1. Gene therapy for HCV/HBV-induced hepatocellular carcinoma

    Current Opinion in Investigational Drugs, Vol. 11, Núm. 12, pp. 1368-1377

2009

  1. Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy

    Molecular Cancer, Vol. 8

  2. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters

    Molecular Therapy, Vol. 17, Núm. 4, pp. 614-622